1102 results about "Human patient" patented technology

This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.

A system for the detection of cardiac events occurring in a human patient is provided. At least two electrodes are included in the system for obtaining an electrical signal from a patient's heart. An electrical signal processor is electrically coupled to the electrodes for processing the electrical signal. The systems receives data regarding the patient's state (e.g. asleep, exercising). Patient state information is stored in a patient state array, thereby enabling the system to track the patient's state over time, and to select an appropriate test for detecting a cardiac event based on both past and present data regarding the patient's state.

Disclosed is a system for delivery of a drug comprising a multiple unit dosing device comprising a housing and an actuator, said device containing multiple doses of multiparticulates comprising drug particles, said device upon actuation delivering a unit dose of said multiparticulates, said drug particles having a mean diameter of greater than 10 mum to about 1 mm such that an effective dose of said drug cannot be delivered into the lower lung of a human patient. Also disclosed are novel methods, devices and dosage forms for delivering a drug.

Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.8 ng/mL/mg and 7.9 ng/mL/mg and an AUC for acetaminophen of between about 28.6 ng*hr/mL/mg and about 59.1 ng*hr/mL/mg (per mg acetaminophen administered) after a single dose.

A method and apparatus are disclosed for a high-throughput, large-scale molecular profiling of tissue specimens by retrieving a donor tissue specimen from an array of donor specimens, placing a sample of the donor specimen in an assigned location in a recipient array, providing substantial copies of the array, performing a different biological analysis of each copy, and storing the results of the analysis. The results may be compared to determine if there are correlations or discrepancies between the results of different biological analyses at each assigned location, and also compared to clinical information about the human patient from which the tissue was obtained. The results of similar analyses on corresponding sections of the array can be used as quality control devices, for example by subjecting the arrays to a single simultaneous investigative procedure. Uniform interpretation of the arrays can be obtained, and compared to interpretations of different observers.

The present invention has multiple aspects relating to assembled self fixing bone-tendon-bone (BTB) grafts and BTB implants. A preferred application in which self fixing assembled bone-tendon-bone (BTB) grafts and implants of the present technology can be used is for ACL repairs in a human patient. In one embodiment, a self fixing BTB graft is characterized by the presence of threads along at least a portion of the exterior surface of one or both bone blocks. In another embodiment, a self fixing assembled bone-tendon-bone implant comprises a removable tendon tensioner which imparts a predetermined tension on the tendon of the BTB graft. In this embodiment, the tensioner can be narrower than the diameter of the bone blocks or can be threaded such that the threads are continuous with the threads of at least one of the bone blocks. The threads facilitate the simultaneous implantation of the leading and trailing bone blocks of the BTB graft in tapped (threaded) holes in the tibia and the femur of a recipient patient. The tensioner maintains the tension on the tendon and the spacing between the bone blocks until the leading bone block is fixed (threaded) in the tapped hole in the femur and the trailing bone block is fixed (threaded) into the tapped tibial bone tunnel. Once the bone blocks are substantially in their fixed positions, the tensioner is removed arthroscopically in the joint space between the tibia and the femur.

A flexible medical intubation instrument provided for placement into an animal or human patient comprises a catheter with at least a pair of longitudinally extending lumens or channels including a sensor and/or actuator channel and a working channel. In the sensor/actuator channel is provided a fixed or slideably removable sensor cable having a sensor for sensing a characteristic or condition including any of the following: a visual sensor for optical viewing, a chemical sensor, a pH sensor, a pressure sensor, an infection sensor, an audio sensor, or a temperature sensor. The sensors are coupled by the sensor/actuator cable through light transmission, electric current, or radio transmission to a viewing instrument or other output device such as a meter or video screen for displaying the condition that is sensed within the body of the patient while the flexibility of the composite structure comprising the catheter and cable enable the entire instrument to flex laterally as it moves through curved passages or around obstructions during insertion or removal. While making observations through the sensor channel, the working channel simultaneously functions as a drain or an irrigation duct, a feeding tube, or to provide a passage for the insertion of one or a succession of surgical devices such that the catheter serves as a protective artificial tract or liner as surgical devices are inserted and removed through it in succession so as to minimize tissue trauma, infection, and pain experienced by the patient. The instrument can be used in urology, as well as a visually directed nasogastric tube, as a visually directed external gastrostomy tube, or as a visually directed internal gastric tube or percutaneous endoscopic gastrostomy tube and in other applications.

An apparatus and method for stimulating animal tissue (for example to trigger a nerve action potential (NAP) signal in a human patient) by application of both electrical and optical signals for treatment and diagnosis purposes. The application of an electrical signal before or simultaneously to the application of a NAP-triggering optical signal allows the use of a lower amount of optical power or energy than would otherwise be needed if an optical signal alone was used for the same purpose and effectiveness. The application of the electrical signal may precondition the nerve tissue such that a lower-power optical signal can be used to trigger the desired NAP, which otherwise would take a higher-power optical signal were the electric signal not applied. Some embodiments include an implanted nerve interface having a plurality of closely spaced electrodes placed transversely and/or longitudinally to the nerve and a plurality of optical emitters.

A method of relieving analgesia and reducing inflammation using a cannabinoid delivery topical liniment composition containing from about 97.5% to about 99.5% by weight a 70% monohydric alcohol solution, and from about 0.5% to about 2.5% by weight of a synergistic cannabinoid mixture extracted from the female plant Cannabis sativa L, including in combination: 9-Tetrahydrocannabinol (delta-9-THC), 9-THC Propyl Analogue (THC-V), Cannabidiol (CBD), Cannabidiol Propyl Analogue (CBD-V), Cannabinol (CBN), Cannabichromene (CBC), Cannabichromene Propyl Analogue (CBC-V), Cannabigerol (CBG), terpenoids, and flavonoids. The liniment is applied topically, preferably by spraying, and the constituents of the mixture are absorbed through the skin and interact with cannabinoid receptors in the body and tissues of a human patient to produce therapeutic analgesic and anti-inflammatory effects without undesirable psychotropic side effects.

The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.

An apparatus for selectively positioning intraoral anatomic features of a human patient to enhance upper airway stability for use alone or in combination with positive airway pressure as therapeutic treatment for obstructive sleep apnea and other conditions, such as snoring, which are symptomatic of upper airway instability.

A device and method for the treatment of sleep apnea and/or snoring in a human patient includes at least one electrode stimulator for providing direct electrical stimulation to a throat and/or laryngeal muscles of the patient. The stimulator is constructed and arranged to be positioned at the throat and/or laryngeal muscles of the patient, either on the surface or subcutaneously. A power source provides a continuous electrical signal to the stimulator so that the throat and/or laryngeal muscles of the patient are contracted to open the airway of the patient. The power source can be a portable source remote from the electrode or a pacemaker unit also implanted in the patient.

The present invention is directed to a compound, method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N⁴-acylcytosine-1,3-dioxolane and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

A cardiac event microrecorder comprising a hermetically sealed housing is shaped and dimensioned to facilitate the subcutaneous implantation of the microrecorder in a human patient by injection through the lumen of a hypodermic needle. The housing comprises a tubular central section of an electrically insulating material, the central section having spaced apart extremities. An electrically conductive sense electrode is secured to and seals each extremity. The housing may have an interior enclosing (1) electrical circuitry for processing, storing and telemetering data representing physiologic information detected by the sense electrodes; (2) a primary cell or rechargeable battery for electrically powering the electrical circuitry; and (3) an inductively couplable charger where a rechargeable battery is used. Also disclosed are a method of subcutaneously implanting a cardiac event recorder in a patient's thoracic region, and a handheld mapping device for determining an optimum location and orientation for the cardiac event microrecorder to be implanted.

A branch vessel in a human patient is located or mapped using in vivo tracked field sensors where in one variation the sensor positions can be located by determining the positions of the sensors relative to a plurality of magnetic field sources of known location. This approach is used, for example, in locating the opening in a renal artery and positioning the proximal end of the AAA stent-graft adjacent to the opening. In another example, the sensors are tracked along the inner wall of an aneurysm and the acquired sensor location data processed to map the contour of the aneurysm to size a prostheses for spanning the aneurysm. The portions of the vessel adjacent the aneurysm also can be mapped. In a further embodiment, an in vivo sensor is positioned in a deployed prosthesis to create a reference for a prosthetic member having a sensor to track to during cannulation of the deployed prosthesis with the prosthetic member.

In one embodiment, a method of fabricating a segmented electrode stimulation lead for implantation within a human patient for stimulation of tissue of the patient, the method comprises: providing a conductive ring, the conductive ring comprising an inner surface and an outer surface, the conductive ring comprising a plurality of grooves provided in the inner surface; electrically coupling a plurality of wires to the conductive ring; forming a stimulation assembly of the lead including the conductive ring and the plurality of wires; and grinding down the outer surface of the stimulation assembly of the lead at least until reaching the plurality of grooves to separate the conductive ring into a plurality of electrically isolated segmented electrodes.

A method of and a device for non-invasively measuring the neurological depressed state and the hemodynamic state of a human patient and involving steps and units of non-invasively measuring EEG, cardiac cycle period, electrical-mechanical interval, mean arterial pressure, and ejection interval and converting the EEG into a neurological index as well as converting the measured electrical-mechanical interval, mean arterial pressure and ejection interval into the cardiac parameters such as Preload, Afterload and Contractility, which are the common cardiac parameters used by an anesthesiologist. A general anesthetic is administered based upon the converted neurological index. A vasoactive agent is independently administered based upon the converted cardiac parameters as necessary in order to restore cardiovascular homeostasis in the patient. The converted neurological and hemodynamic state of a patient are displayed on a screen as an index value and a three-dimensional vector with each of its three coordinates respectively representing Preload, Afterload and Contractility. Therefore, a medical practitioner looks at the screen and quickly obtains the important and necessary information.